274 results on '"Sohn, Joo Hyuk"'
Search Results
52. Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy
53. Retargeting of adenoviral gene delivery via Herceptin–PEG–adenovirus conjugates to breast cancer cells
54. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer
55. Phase 2 Study of TAS-117 in Advanced Solid Tumors Harboring Phosphatidylinositol 3-Kinase/v-akt Murine Thymoma Viral Oncogene Homolog Gene Aberrations
56. Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
57. A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer
58. Metaplastic breast cancer: clinicopathological features and its prognosis
59. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
60. Abstract P3-08-33: Intermediate HER2 expression predicts poor prognosis in ER (+) breast cancer patients aged 55 and older
61. Establishment of chemosensitivity tests in triple-negative and BRCA-mutated breast cancer patient-derived xenograft models
62. A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy
63. WEEKLY 5-FLUOROURACIL PLUS CISPLATIN FOR CONCURRENT CHEMORADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK CANCER
64. Phase Ii Trial of Irinotecan and Cisplatin With Early Concurrent Radiotherapy in Limited-Disease Small-Cell Lung Cancer
65. Adenosine Triphosphate-Based Chemotherapy Response Assay (Atp-Cra)-Guided Platinum-Based 2-Drug Chemotherapy for Unresectable Nonsmall-Cell Lung Cancer
66. Risk of Lymphedema Following Contemporary Treatment for Breast Cancer
67. Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)
68. A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial
69. External validation of IBTR! 2.0 nomogram for prediction of ipsilateral breast tumor recurrence
70. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients
71. An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer
72. Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study
73. Do Recent Advances in Diagnostic and Therapeutic Procedures Negate the Benefit of Postmastectomy Radiotherapy in N1 Patients With a Low Risk of Locoregional Recurrence?
74. Abstract P5-19-07: Randomized Phase II trial of afatinib alone or with vinorelbine versus investigator's choice of treatment in patients with HER2-positive breast cancer with progressive brain metastases after trastuzumab and/or lapatinib-based therapy: LUX-Breast 3
75. Abstract OT2-4-02: Testing BRCA 1/2 mutation using next generation sequencing (BRCANGS)
76. Abstract P3-10-04: A open-label, randomized, parallel, phase III trial to evaluate the efficacy and safety of Genexol®-PM compared to Genexol®(conventional paclitaxel with cremorphor EL) in recurrent or metastatic breast cancer patients
77. Abstract P6-08-33: Prognostic value of axillary nodal ratio after neoadjuvant chemotherapy of AC followed by docetaxel: A multicenter retrospective cohort study
78. Predictions for short- and long-term survival after ICU admission in advanced cancer patients.
79. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer
80. PR99 QUALITY OF LIFE (QOL) IN METASTATIC BREAST CANCER PATIENTS WITH MAINTENANCE PACLITAXEL PLUS GEMCITABINE (PG) CHEMOTHERAPY: RESULTS FROM PHASE III, MULTICENTER, RANDOMIZED TRIAL OF MAINTENANCE CHEMOTHERAPY VERSUS OBSERVATION (KCSG-BR07-02)
81. Phase III, Multicenter, Randomized Trial of Maintenance Chemotherapy Versus Observation in Patients With Metastatic Breast Cancer After Achieving Disease Control With Six Cycles of Gemcitabine Plus Paclitaxel As First-Line Chemotherapy: KCSG-BR07-02
82. Abstract 1212: Anaplastic lymphoma kinase (ALK) gene copy number gain in inflammatory breast cancer (IBC): frequency, clinicopathologic features and prognostic implication .
83. A phase III, multicenter, randomized trial of maintenance versus observation after achieving clinical response in patients with metastatic breast cancer who received six cycles of gemcitabine plus paclitaxel as first-line chemotherapy (KCSG-BR 0702, NCT00561119).
84. A multicenter phase II neoadjuvant trial of bevacizumab combined with docetaxel plus carboplatin in the treatment of triple-negative breast cancer: Korean Cancer Study Group (KCSG-BR 0905, NCT 01208480).
85. Abstract C10: Class III β -tubulin predicts pathological response to neoadjuvant docetaxel-based chemotherapy in breast cancer patients.
86. Abstract 5178: Expression of CD44/CD24 and aldehyde dehydrogenase 1 in resected breast cancer: CD24-positivity predicts early relapse
87. A phase I study of nimotuzumab in combination with radiotherapy in stages IIB–IV non-small cell lung cancer unsuitable for radical therapy: Korean results
88. Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: A phase II trial
89. Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
90. Abstract 1277: Differential roles of TRAIL death receptors during TRAIL-induced signaling pathways
91. Abstract 1276: TRAIL-induced p38 activation responsible for increases of Akt catalytic and Invasive activity
92. Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance
93. Weekly 5‐fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer
94. Phase II Study of Transarterial Holmium-166-Chitosan Complex Treatment in Patients with a Single, Large Hepatocellular Carcinoma
95. Brain metastases from hepatocellular carcinoma: prognostic factors and outcome
96. Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients
97. P2-190: The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC
98. P2-288: Retrospective comparison of adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided chemotherapy versus empirical chemotherapy in unresectable nonsmall cell lung cancer
99. P1-041: Impact of second hand smoke(SHS) exposure on the likelihood of mutations in epidermal growth factor receptor(EGFR) gene in patients with non-small cell lung cancer(NSCLC) who had never smoked
100. Phase II Study of Erlotinib in Advanced Non–Small-Cell Lung Cancer After Failure of Gefitinib
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.